EVIDENCE LIBRARY
Ketamine Dose Trial Used Midazolam as an Active Placebo and Found Time-Specific Differences
A depression trial compared several ketamine doses with midazolam. The benzodiazepine’s role was to provide an active comparator, not an established antidepressant treatment.
A depression trial compared several ketamine doses with midazolam. The benzodiazepine’s role was to provide an active comparator, not an established antidepressant treatment.
The results over time
Ninety-nine participants were randomized across five small groups. Standard and higher ketamine doses showed adjusted advantages over midazolam primarily at day one. Adjusted pairwise differences were not significant at day three.
Higher doses also produced more dissociative symptoms and transient blood-pressure elevation. Low-dose results changed when multiple comparisons were accounted for.
What the comparator means
An active placebo can mimic some immediate drug effects without guaranteeing successful blinding. Distinctive ketamine effects may reveal assignment, while groups of roughly twenty provide imprecise estimates.
The study does not establish midazolam as a depression therapy or prove sustained ketamine superiority at every follow-up. A faithful account identifies the endpoint, time point, adjustment, and comparator dose. It also separates a single-infusion experiment from evidence about repeated long-term treatment or benzodiazepine co-prescribing.
Source paper
Original analysis of the supplied journal article, identified as PMC6447473.